These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid. Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, Kamijo R. Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783 [Abstract] [Full Text] [Related]
6. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P. BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769 [Abstract] [Full Text] [Related]
7. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T. Ann Oncol; 2015 Oct 22; 26(10):2149-54. PubMed ID: 26205395 [Abstract] [Full Text] [Related]
14. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T. J Orthop Surg (Hong Kong); 2020 Oct 22; 28(2):2309499020929786. PubMed ID: 32539628 [Abstract] [Full Text] [Related]
15. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T. BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567 [Abstract] [Full Text] [Related]
16. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone. Li M, Wang W, Zhu Y, Lu Y, Wan P, Yang K, Zhang Y, Mao C. Acta Biomater; 2018 Sep 01; 77():365-379. PubMed ID: 30030174 [Abstract] [Full Text] [Related]
17. Giant cell tumour of bone in the denosumab era. van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H. Eur J Cancer; 2017 May 01; 77():75-83. PubMed ID: 28365529 [Abstract] [Full Text] [Related]
18. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Gouin F, Rochwerger AR, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F, Anract P. Eur J Cancer; 2014 Sep 01; 50(14):2425-31. PubMed ID: 25088085 [Abstract] [Full Text] [Related]
19. Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update. Tsukamoto S, Mavrogenis AF, Masunaga T, Honoki K, Fujii H, Kido A, Tanaka Y, Errani C. Curr Oncol; 2024 Apr 08; 31(4):2112-2132. PubMed ID: 38668060 [Abstract] [Full Text] [Related]
20. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Eur J Surg Oncol; 2018 Sep 08; 44(9):1384-1390. PubMed ID: 29650420 [Abstract] [Full Text] [Related] Page: [Next] [New Search]